Haimovis 24mg/3ml syringe, 2 pcs.

Haimovis® is a hydrogel that is produced according to Good Manufacturing Practice (GMP) and contains HYADD®4, a new molecule patented by Fidia, at a concentration of 8 mg/ml. HYADD®4 is a new hyaluronic acid derivative: partial hyaluronic acid hexadecylamide (partial due to the very low level of hyaluronic acid modification, at approximately 3% molar concentration to maintain biocompatibility).

Indications

Active ingredient

Composition

Directions for use

Synopsis

Contraindications

Side effects

Local pain, swelling, fever, and redness may rarely occur at the injection site; such symptoms are usually mild and passable.

More severe inflammatory reactions have been reported, with precipitation of sodium pyrophosphate crystals when sodium hyaluronate solutions are injected intra-articularly, although no relationship has been identified.

If general precautions are not followed and the injection site is not aseptically treated, septic arthritis may occur in rare cases, as for any intra-articular treatment.

Similarities